Developing Technologies For Tomorrow’s Therapies

Caladrius is expanding the potential of cell therapies to treat disease through a unifying platform approach that will yield a robust, balanced pipeline targeting critical unmet needs. Our three technology platforms target immuno-oncology, ischemic repair, and immune modulation.

Caladrius' CLBS20 Phase 3 Intus Study

Patient enrollment for Caladrius’ CLBS20 Phase 3 metastatic melanoma study (called, the Intus Study) is now open. If you are interested in learning more about the study, please visit www.theintusstudy.com or the trial’s listing on clinicaltrial.gov.